AI assistant
Vanta Bioscience Limited Interim / Quarterly Report 2026
62013_rns_2026-05-30_eeeac5df-9470-4dc5-b50e-d96b584bc41e.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
VBS
Vanta Bioscience Limited
Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website: www.vantabio.com
Email : [email protected]
CIN No. : L74999TG2016PLC109280
May 30, 2026
Secunderabad
To
Corporate Compliance Dept.
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001, Maharashtra
Sub: Outcome of the Board Meeting held on 30.05.2026
Ref: Scrip Code: 540729 | Scrip ID: VANTABIO
Dear Sir/Madam
This is to inform you that the Board of Directors at its meeting held today i.e., Saturday, May 30, 2026, inter alia considered and approved the following:
-
Audited standalone and consolidated Financial Results for the half year and financial year ended March 31, 2026 along with Audit Reports for the period ended March 31, 2026 The same has been enclosed herewith.
-
Re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as Managing Director for another period of 3 years w.e.f April 18, 2026 subject to the approval of the shareholders and necessary compliances. Brief Profile and other details are annexed.
It is hereby declared/certified that the statutory auditors of the Company have submitted their Audit Reports on the Audited standalone and consolidated financial results of the Company for the FY 2025-26 with an unmodified and unqualified opinion.
The meeting commenced at 06.00 PM and concluded at 07:00 PM.
This is for your information and dissemination to the public.
Thanking You
Yours Faithfully
For Vanta Bioscience Limited
MULAKALA Digitally signed by MULAKALA
DOPESH RAJA
Date: 2026.05.30
20:12:14 +05'30'
Mulakala Dopesh Raja
Managing Director
DIN: 01176660
The Right Dose of
Intelligent Toxicology
Research Center :
K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel: 044 6790 1600
VBS
Vanta Bioscience Limited
Regd. Office : 1-20-248, Umajay Complex, Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website: www.vantabio.com
Email : [email protected]
CIN No. : L74999TG2016PLC109280
Declaration pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015
I, Mulakala Dopesh Raja, Managing Director of Vanta Bioscience Limited (the Company) hereby declare that, the Statutory Auditors of the Company, M/s Mathesh & Ramana, Chartered Accountants have issued unmodified opinion on the Audited Standalone and consolidated Financial Results of the Company for the half year and year ended March 31, 2026.
This declaration is issued in compliance of Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2016 read with amendments, circulars and other provisions as applicable
For Vanta Bioscience Limited
MULAKALA DOPESH RAJA
Digitally signed by MULAKALA DOPESH RAJA
Date: 2026.05.30 20:12:41 +03'30'
Mulakala Dopesh Raja
Managing Director
DIN: 01176660
30.05.2026
Hyderabad
The Right Dose of Intelligent Toxicology
Research Center :
K2-B, 11th Cross Street, SIPCOT Industrial Complex, Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600
VBS
Vanta Bioscience Limited
Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website: www.vantabio.com
Email : [email protected]
CIN No. : L74999TG2016PLC109280
Annexure
Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
| Particulars | Mr. Dopesh Raja Mulakala |
|---|---|
| Reason for change viz. | |
| Resignation/ appointment | Re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as the Managing Director of the Company for a further term of three (3) years with effect from April 18, 2026, up to April 17, 2029 subject to the approval of shareholders and necessary compliances |
| Date of Appointment / Cessation—and terms of appointment | Re-appointment of Mr. Dopesh Raja Mulakala as the Managing Director of the Company for a further term of three (3) years with effect from April 18, 2026, up to April 17, 2029 subject to the approval of shareholders and necessary compliances |
| Brief profile (in case of appointment) | Mr. Dopesh Raja Mulakala has a master’s in business administration from the Weatherhead School of Management at Case Western Reserve University, U.S.A. He holds a PGDMA (Family Managed Business) from S.P. Jain Institute of Management & Research, Mumbai, India. He holds a bachelor’s degree of engineering – mechanical (production) from Osmania University, Hyderabad, India. He is a member of CII FBN (India Chapter), Pharmaceutical Export Promotion Council (PHARMEXIL) and Federation of Indian Exporting Organisations (FIEO). He has experience of more than 10 years in setting up and running companies in the areas of manufacturing, research & development and is one of the promoters of Sarvotham Group – Hyderabad, India. |
| Relationships with other any Directors (in case of appointment) | NA |
| Information as required pursuant to BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated June 20, 2018. | He is not debarred from holding the office of Director/Managing Director by virtue of any SEBI order or any other such authority or under any provision of law. |
The Right Dose of
Intelligent Toxicology
Research Center :
K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600
| VANTA BIOSCIENCE LIMITED | ||||||
|---|---|---|---|---|---|---|
| NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003 | ||||||
| CIN L74999TG2016PLC109280 | ||||||
| STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2026 | ||||||
| (Rupees. In Lacs) | ||||||
| Sr.No | Particulars | STANDALONE | ||||
| 6 MONTH ENDED | YEAR ENDED | |||||
| 31.03.2026 | 30.09.2025 | 31.03.2025 | 31.03.2026 | 31.03.2025 | ||
| (Audited | (Un Audited) | (Audited | (Audited) | (Audited) | ||
| 1 | Income | |||||
| Revenue from Operation | 151.46 | 30.18 | 32.65 | 181.64 | 112.74 | |
| Other Income | 15.95 | 0.00 | 3.92 | 15.95 | 3.92 | |
| Total Revenue | 167.41 | 30.18 | 36.57 | 197.59 | 116.66 | |
| 2 | Expenses | |||||
| a) Cost of material Consumed | 1.71 | 12.41 | -10.78 | 14.12 | 7.35 | |
| b) Changes In Inventories : Work in progress | 23.78 | (127.16) | 250.64 | -103.38 | 98.95 | |
| c) Employee Benfit Expenses | (37.18) | 98.33 | -51.33 | 61.15 | 58.29 | |
| d) Financial Cost | (10.54) | 88.27 | -6.13 | 77.73 | 66.26 | |
| e) Depreciation and amortization Exp | (22.71) | 61.48 | -17.49 | 38.77 | 44.00 | |
| f) other expenses | 23.77 | 82.90 | 11.25 | 106.67 | 113.72 | |
| Total Expenses | (21.17) | 216.23 | 176.16 | 195.06 | 388.57 | |
| 3 | Profit/(Loss) from ordinary activities before Exceptional Items (1-2) | 188.58 | (186.05) | (139.59) | 2.53 | (271.91) |
| 4 | Exceptional Items Income /(Expenses) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | Profit/(Loss) from ordinary activities before tax (3+4) | 188.58 | (186.05) | (139.59) | 2.53 | (271.91) |
| 6 | Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7 | Net Profit/(Loss) after Minority Interest (5-6) | 188.58 | (186.05) | (139.59) | 2.53 | (271.91) |
| 8 | Tax Expenses | |||||
| a) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| b) MAT Credit Availed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| c) Deferred Tax | (4.72) | (4.73) | (2.98) | (9.45) | (5.96) | |
| 9 | Net Profit/(Loss) from ordinary activities after tax (7+8) | 193.30 | (181.32) | (136.61) | 11.98 | (265.95) |
| 10 | Other Comprehensive Income / (expenses) for the year, net of tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 | Total Comprehensive Income/(Loss) Net of Tax (9+10) | 193.30 | (181.32) | (136.61) | 11.98 | (265.95) |
| 12 | Paid up Equity share capital (face value of Rs.10/-) | 711.20 | 711.20 | 631.20 | 711.20 | 631.20 |
| 13 | Reserve excluding Revaluation reserve | |||||
| 14 | Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) | |||||
| a) Basic (Rs.) | 2.72 | -2.55 | -2.16 | 0.17 | -4.21 | |
| b) Diluted (Rs.) | 2.72 | -2.55 | -2.16 | 0.17 | -4.21 | |
| Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) | ||||||
| a) Basic (Rs.) | 2.72 | -2.55 | -2.16 | 0.17 | -4.21 | |
| b) Diluted (Rs.) | 2.72 | -2.55 | -2.16 | 0.17 | -4.21 |
Place : Hyderabad
Date : 30.05.2026
For Vanta Bioscience Limited
Dopesh Raja Mulakala
Managing Director
| VANTA BIOSCIENCE LIMITED | ||||||
|---|---|---|---|---|---|---|
| NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003 | ||||||
| CIN L74999TG2016PLC109280 | ||||||
| STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2026 | ||||||
| (Rupees. In Lacs) | (Rupees. In Lacs) | |||||
| Sr.No | Particulars | CONSOLIDATED | ||||
| 6 MONTH ENDED | YEAR ENDED | |||||
| 31.03.2026 | 30.09.2025 | 31.03.2025 | 31.03.2026 | 31.03.2025 | ||
| (Audited) | (Un Audited) | (Audited) | (Audited) | (Audited) | ||
| 1 | Income | |||||
| Revenue from Operation | 151.46 | 30.18 | 32.65 | 181.64 | 112.74 | |
| Other Income | 15.95 | 0.00 | 3.92 | 15.95 | 3.92 | |
| Total Revenue | 167.41 | 30.18 | 36.57 | 197.59 | 116.66 | |
| 2 | Expenses | |||||
| a) Cost of material Consumed | 1.72 | 12.41 | -10.77 | 14.13 | 7.35 | |
| b) Changes In Inventories : Work in progress | 23.78 | (127.16) | 250.64 | (103.38) | 98.95 | |
| c) Employee Benfit Expenses | -37.18 | 98.33 | -51.34 | 61.15 | 58.28 | |
| d) Financial Cost | -10.54 | 88.27 | -6.13 | 77.73 | 66.26 | |
| e) Depreciation and amortization Exp | -22.71 | 61.48 | -17.48 | 38.77 | 44.01 | |
| f) other expenses | 24.35 | 83.47 | 12.06 | 107.82 | 114.86 | |
| Total Expenses | -20.58 | 216.80 | 176.98 | 196.22 | 389.71 | |
| 3 | Profit/(Loss) from ordinary activities before Exceptional Items (1-2) | 187.99 | (186.62) | (140.41) | 1.37 | (273.05) |
| 4 | Exceptional Items Income /(Expenses) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | Profit/(Loss) from ordinary activities before tax (3+4) | 187.99 | (186.62) | (140.41) | 1.37 | (273.05) |
| 6 | Minority Interest | 0.00 | ||||
| 7 | Net Profit/(Loss) after Minority Interest (5-6) | 187.99 | (186.62) | (140.41) | 1.37 | (273.05) |
| 8 | Tax Expenses | |||||
| a) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| b) MAT Credit Availed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| c) Deferred Tax | -4.73 | (4.73) | -2.98 | (9.46) | (5.96) | |
| 9 | Net Profit/(Loss) from ordinary activities after tax (7+8) | 192.72 | (181.89) | (137.43) | 10.83 | (267.09) |
| 10 | Other Comprehensive Income / (expenses) for the year, net of tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 | Total Comprehensive Income/(Loss) Net of Tax (9+10) | 192.72 | (181.89) | (137.43) | 10.83 | (267.09) |
| 12 | Paid up Equity share capital (face value of Rs.10/-) | 711.20 | 711.20 | 631.20 | 711.20 | 631.20 |
| 13 | Reserve excluding Revaluation reserve | |||||
| 14 | Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) | |||||
| a) Basic (Rs.) | 2.71 | -2.56 | -2.18 | 0.15 | -4.23 | |
| b) Diluted (Rs.) | 2.71 | -2.56 | -2.18 | 0.15 | -4.23 | |
| Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) | ||||||
| a) Basic (Rs.) | 2.71 | -2.56 | -2.18 | 0.15 | -4.23 | |
| b) Diluted (Rs.) | 2.71 | -2.56 | -2.18 | 0.15 | -4.23 |
Place : Hyderabad
Date : 30.05.2026
For Vanta Bioscience Limited
Dopesh Raja Mulakala
Managing Director
| STATEMENT OF ASSETS & LIABILITIES AS ON 31st MARCH 2026 | |||||
|---|---|---|---|---|---|
| Sr. | |||||
| No | Particulars | STANDALONE | CONSOLIDATED | ||
| 31.03.2026 | 31.03.2025 | 31.03.2026 | 31.03.2025 | ||
| Audited | Audited | Audited | Audited | ||
| A | Equity and Liabilities | ||||
| 1 | EQUITY | ||||
| a) Equity share capital | 711.20 | 631.20 | 711.20 | 631.20 | |
| b) Reserve & Surplus | 1414.12 | 1082.14 | 1406.36 | 1075.54 | |
| Sub total Equity | 2125.32 | 1713.34 | 2117.56 | 1706.74 | |
| 2 | LIABILITIES | ||||
| Non Current Liabilities | |||||
| a) Financial Liabilities | |||||
| i) Borrowings | 3120.76 | 1939.13 | 3120.76 | 1939.13 | |
| b) Provisions | 0.00 | 0.00 | 0.00 | 0.00 | |
| c) Deferred tax Liabilities | 64.82 | 74.27 | 64.82 | 74.27 | |
| d) Other Non Current Liabilities | 125.00 | 0.00 | 125.00 | 0.00 | |
| Sub Total -Non Current Liabilities | 3310.58 | 2013.40 | 3310.58 | 2013.40 | |
| 3 | Current Liabilities | ||||
| a) Financial Liabilities | |||||
| i) Borrowings | 687.06 | 1108.00 | 687.06 | 1108.00 | |
| ii) Trade Payables | |||||
| (a) Total Outstanding dues of Micro Enterprises and Small Enterprises | |||||
| (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises | 154.35 | 269.48 | 160.89 | 369.78 | |
| iii) Other Current Liabilities | 334.12 | 479.57 | 334.17 | 479.62 | |
| iv) Provisions | 0.00 | 0.00 | 0.00 | 0.00 | |
| v) Current tax Liabilities(net) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sub Total -Non Current Liabilities | 1175.53 | 1857.05 | 1182.12 | 1957.40 | |
| Total Equity and Liabilities | 6611.43 | 5583.79 | 6610.26 | 5677.54 | |
| B | ASSETS | ||||
| 1 | Non Current Assets | ||||
| a) Property, Plant and Equipment | 967.69 | 1089.78 | 967.69 | 1089.78 | |
| b) Capital Work in Progress | 0.00 | 0.00 | 0.00 | 0.00 | |
| c) Other Intangible assets | 3840.02 | 3153.71 | 3840.02 | 3153.71 | |
| d) Other Intangible assets under development | 0.00 | 0.00 | 0.00 | 0.00 | |
| e) Investment in associates and joint ventres | 0.00 | 0.00 | 0.00 | 0.00 | |
| f) Financial Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| i) Investments in Subsidiary | 300.00 | 300.00 | 300.00 | 300.00 | |
| ii) Loans | 0.00 | 0.00 | 0.00 | 0.00 | |
| iii) Other Financial Assets | 0.00 | 0.00 | 88.40 | 88.40 | |
| g) Deferred tax assets (net) | 0.00 | 0.00 | 0.00 | 0.00 | |
| h) Other non current assets | 0.94 | 0.94 | 0.94 | 0.94 | |
| Sub Total Non-CurrentAssets | 5108.65 | 4544.43 | 5197.05 | 4632.83 | |
| 2 | Current Assets | ||||
| a) Inventories | 752.75 | 648.27 | 752.75 | 648.27 | |
| b) Financial Assets | |||||
| i) Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| ii) Trade Receivable | 255.83 | 174.48 | 255.84 | 174.47 | |
| iii) Bank, Cash and Cash equivalents | 12.93 | 14.14 | 13.54 | 14.76 | |
| iv) Loans & Advances | 427.95 | 155.24 | 337.76 | 159.97 | |
| iv) Other Financial Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| c) Current Tax Assets (net) | 0.00 | 0.00 | 0.00 | 0.00 | |
| d) Other Current Assets | 53.32 | 47.23 | 53.32 | 47.24 | |
| Sub Total Current Assets | 1502.78 | 1039.36 | 1413.21 | 1044.71 | |
| Total Assets | 6611.43 | 5583.79 | 6610.26 | 5677.54 |
Place : Hyderabad
Date : 30.05.2026
For Vanta Bioscience Limited
Dopesh Raja Mulakala
Managing Director
| VANTA BIOSCIENCE LIMITED | ||||
|---|---|---|---|---|
| Cash Flow statement for the period ended 31st March,2026 | (Rupees in Lacs) | |||
| Particulars | STANDALONE | CONSOLIDATED | ||
| For the Year ended 31.03.2026 | For the Year ended 31.03.2025 | For the Year ended 31.03.2026 | For the Year ended 31.03.2025 | |
| A. Cash Flow from Operating Activities | ||||
| Profit before exceptional, Extraordinary items and Tax | 2.53 | (271.91) | 1.37 | (273.05) |
| Adjustment for: | ||||
| Depreciation | 123.02 | 122.97 | 123.02 | 122.97 |
| Finance Charges | 77.73 | 66.26 | 77.73 | 66.26 |
| Profit on Sale of Fixed Assets | - | - | - | - |
| Sub total | 200.75 | 189.23 | 200.75 | 189.23 |
| Operating profit Before Working Capital Changes | 203.28 | -82.68 | 202.12 | -83.82 |
| Adjustment for: | ||||
| (Increase) /Decrease in Inventories | (104.48) | 100.21 | (104.48) | 100.21 |
| (Increase) /Decrease in Trade receivables | (81.36) | 59.25 | (81.36) | 59.25 |
| Increase /(Decrease) in Current liabilities | (260.57) | 55.58 | (354.34) | 56.74 |
| (Increase) /Decrease Loans & Advances | (278.80) | 3.78 | (183.88) | 3.69 |
| (Increase) /Decrease Current Assets | - | - | - | - |
| (Increase) /Decrease in Current Investment | 0.00 | 0.00 | - | - |
| Sub total | -725.21 | 218.82 | -724.06 | 219.89 |
| Cash Generated from operations | -521.93 | 136.14 | -521.94 | 136.07 |
| Net Cash Flow from Operating Activities | -521.93 | 136.14 | -521.94 | 136.07 |
| B: Cash Flow from Investing Activities | ||||
| Purchase of Fixed Assets | (0.93) | - | (0.93) | - |
| Capital Work in progress | - | - | - | - |
| Capital Work in progress-R&D | (686.31) | (579.00) | (686.31) | (579.01) |
| proceeds from sale of Fixed Assets | - | - | - | - |
| Investment in Subsidiaries | - | - | - | - |
| Purchase of other Non current Investments | - | - | - | - |
| Net Cash Flow from Investing Activities | (687.24) | (579.00) | (687.24) | (579.01) |
| C: Cash Flow from Financing Activities | ||||
| Increase /(Decrease) in Unsecured Loan | - | - | - | - |
| Increase /(Decrease) in Working capital | (420.94) | 381.19 | (420.94) | 381.19 |
| Increase /(Decrease) in Term Loan | 1,181.63 | 127.93 | 1,181.63 | 127.93 |
| Increase /(Decrease) Other Long Term Liabilities | 125.00 | 0.00 | 125.00 | - |
| Increase /(Decrease) in share capital | -80.00 | - | 80.00 | - |
| Increase /(Decrease) in share Premium | 320.00 | - | 320.00 | - |
| Finance Charges | (77.73) | (66.26) | (77.73) | (66.26) |
| Net Cash Flow from Financing Activities | 1,207.96 | 442.86 | 1,207.96 | 442.86 |
| Actual Payment of Income Tax | - | - | - | - |
| D: Net Increase/Decrease in Cash and cash Equivalents | -1.21 | 0.00 | -1.22 | -0.08 |
| Opening of Cash & Cash Equivalents | 14.14 | 14.14 | 14.76 | 14.84 |
| Closing Balance of Cash & Cash Equivalents | 12.93 | 14.14 | 13.54 | 14.76 |
See accompanying notes to the financial statements
As per our report of even date annexed.
Place : Hyderabad
Date : 30.05.2026
For Vanta Bioscience Limited
Dopesh Raja Mulakala
Managing Director
Notes to Standalone and consolidated financial statements:
-
The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30.05.2026
-
As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
-
Statement of Assets and Liabilities as on 31st March, 2026 is enclosed herewith.
-
Statement of Cash flow for the period ended 31st March, 2026 is enclosed herewith.
-
The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
-
The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
-
The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.
CA
MATHESH & RAMANA
INDIA
CHARTERED ACCOUNTANTS
INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF VANTA BIOSCIENCE LIMITED
Report on the audit of the Standalone Financial Results
Opinion:
We have audited the accompanying standalone half yearly financial results of Vanta Bioscience Limited (the company) for the half year ended 31.03.2026 and the year to date results for the period from 01.04.2025 to 31.03.2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:
i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended 31.03.2026 as well as the year to date results for the period from 01.04.2025 to 31.03.2026.
Basis for Opinion:
We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Management’s Responsibilities for the Standalone Financial Results:
These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the standalone financial statements.
The Company’s Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ‘Interim Financial Reporting’ prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
C
CA
MATHESH & RAMANA
INDIA
CHARTERED ACCOUNTANTS
responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.
In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
The Board of Directors are also responsible for overseeing the Company’s financial reporting process.
Auditor’s Responsibilities for the Audit of the Standalone Financial Results:
Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
HIMAYATNAGAR
CA
INDIA
MATHESH & RAMANA
CHARTERED ACCOUNTANTS
are required to draw attention in our auditor’s report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
Other Matter:
The financial results includes the results for the half year ended 31.03.2026, being the balancing figure between the audited figures in respect of the full financial year ended 31.03.2026 and the published unaudited year-to-date figures of the first half year of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.
For MATHESH & RAMANA
CHARTERED ACCOUNTANTS
Place: Hyderabad
Date: 30.05.2026
UDIN: 26026967CGMZIE9716
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
CA
INDI
MATHESH & RAMANA
CHARTERED ACCOUNTANTS
INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF VANTA BIOSCIENCE LIMITED
Report on the audit of the Consolidated Financial Results
Opinion:
We have audited the accompanying Statement of Consolidated Financial Results of VANTA BIOSCIENCE LIMITED (“Holding company”) and its subsidiaries (holding company and its subsidiaries together referred to as “the Group”), for the half year ended 31.03.2026 and for the period from 01.04.2025 to 31.03.2026 (“the Statement”), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, associates and jointly controlled entities, the Statement:
i. includes the financial results of the following entities:
Vanta Clinical Research Limited (Subsidiary)
ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
iii. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the half year ended 31.03.2026 and for the period from 01.04.2025 to 31.03.2026.
Basis for Opinion:
We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.
Management’s Responsibilities for the Consolidated Financial Results:
These half yearly financial results as well as the year to date consolidated financial results have been prepared on the basis of the consolidated financial statements.
The Holding Company’s Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
C
CA
MATHESH & RAMANA
INDIA
CHARTERED ACCOUNTANTS
other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ‘Interim Financial Reporting’ prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.
In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.
Auditor’s Responsibilities for the Audit of the Consolidated Financial Results:
Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
FIRM: 500 029
C
INDIA
MATHESH & RAMANA
CHARTERED ACCOUNTANTS
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.
E-mail: [email protected]
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863
CA
INDIA
MATHESH & RAMANA
CHARTERED ACCOUNTANTS
Other Matters:
The Consolidated Financial Results include the audited Financial Results of 1 (One) subsidiary, whose Financial Results / financial information reflects total assets of Rs. 393.83 Lakhs as at 31st March 2026 and net profit after tax of Rs. (0.58) Lakhs and Rs. (1.16) Lakhs for the half year ended 31st March 2026 and for the period from 01.04.2025 to 31.03.2026 respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors’ reports on Financial statements / Financial Results / financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.
For MATHESH & RAMANA
CHARTERED ACCOUNTANTS
B. V. RAMANA RÉDDY
M. No. 026967 Partner
Place: Hyderabad
Date: 30.05.2026
UDIN: 26026967TVKMSU6171
E-mail: [email protected]